Studies how a PDE3B gene variant affects fat tissue and blood sugar
Compares fat tissue and sugar handling in people with and without a PDE3B variant.
Key facts
- Who runs it
- Cambridge University Hospitals NHS Foundation Trust
- Where
- Cambridge, United KingdomSee the site
- Trial code
- Registry title
- PDE3B in Metabolic Regulation
- Status
- Enrolling by invitation
- People taking part
- 40 people, planned
- Started
- 1 Sept 2025
- Expected to end
- Sept 2029
- Type of study
- Observational, 2 groups
- Record updated
- 24 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men and women aged 21-75 years. Some carry a PDE3B gene variant and some do not, so researchers can compare fat tissue and sugar and fat handling.
- Age
- 21 to 75 years
- Sex
- Men and women
- Biomarker or test result
- The record mentions people with loss-of-function variants in the PDE3B gene and a paired group without the variant (wild type). The inclusion list itself does not state this.
Main reasons for not taking part
- Weight change of more than 5% in the last 2 months
- Type 2 diabetes or other major organ dysfunction
- Cancer in the last 5 years
- Gastrointestinal or bariatric surgery (except cholecystectomy and appendectomy)
- Smoking, illegal drug use, or being pregnant or breastfeeding
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- willing and able to give informed consent for participation in the study
- aged 21-75 years
- men and women
Who cannot take part
- gastrointestinal or bariatric surgery (except cholecystectomy and appendectomy)
- use of medications that affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued
- illegal drug use
- type 2 diabetes or other major organ dysfunction
- cancer in last 5 years
- conditions that render subject unable to complete all testing procedures (including individuals with known allergies or contraindications to the medications used in this study)
- unstable weight (>5% change the last 2 months)
- smoking
- pregnant or lactating
- unable to grant voluntary informed consent or comply with the study instructions
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 75 years old?
Where in United Kingdom
- Cambridge university hospitalCambridge, United KingdomNo longer taking part
About the trial
What the trial wants to find out
Phosphodiesterase 3B (PDE3B), an enzyme responsible for the degradation of cyclic AMP and GMP (two important second messengers used for intracellular signal transduction), has been associated with cardiometabolic outcomes. Results from animal studies indicate that abolishing PDE3B function may be associated with unfavourable metabolic profile; however, preliminary human studies suggest that heterozygous loss of function (LoF) variants in the PDE3B gene have been associated with cardiometabolic improvements. Therefore, the effect of PDE3B on human adipose tissue metabolic pathways remains poorly understood.
Read full original descriptionShow less
Accordingly, the investigators propose to conduct a recall-by-genotype, case-control study in a group of people with LoF variants in the PDE3B gene and a matched group without the variant (wild type, WT) to determine differences on key metabolic features: 1) adipose tissue biology (i.e., mitochondrial function, adipocyte morphology, gene expression and in vivo lipolysis in the basal and/or the insulin-stimulated state); 2) systemic lipid and glucose metabolism using the hyperinsulinemic-euglycemic clamp procedure.
The proposed investigations will elucidate the role of PDE3B on adipose tissue and systemic glucose and lipid metabolism in humans and whether modulating PDE3B activity constitutes a target for the prevention and treatment of cardiometabolic disease.
The 2 groups in the trial
- PDE3B LoF group
Individuals heterozygous for a loss-of-function variant in the PDE3B gene
- Wild type group
Individuals who do not carry the loss-of-function variant for PDE3B gene but otherwise matched for age, sex, race/ethnicity, and body fat percent.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Role of Phosphodiesterase 3B in the Regulation of Human Adipose Tissue Biology and Systemic Glucose and Lipid Homeostasis
- Plain-language title
- Studies how a PDE3B gene variant affects fat tissue and blood sugarGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06533007, who can take part
- Record updated
- 24 November 2025